An aminopyridine compound that may be used as an aldehyde trapping agent, and specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

##STR00001##

The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs. ##STR00001##

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

The present disclosure relates to the preparation of pyridine derivatives, such as α-picoline or α-parvoline, and catalysts useful for the selective preparation of such pyridine derivatives. Particularly, the present disclosure relates to the selective preparation of certain pyridine derivative using dealuminated zeolite catalysts.

The present disclosure relates to the preparation of pyridine derivatives, such as α-picoline or α-parvoline, and catalysts useful for the selective preparation of such pyridine derivatives. Particularly, the present disclosure relates to the selective preparation of certain pyridine derivative using dealuminated zeolite catalysts.

The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.

The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.

Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.

The present invention discloses Octenidine based compounds of formula (A) or formula (B) and formula (C) where in, n=1, 2, 3, 4 and R′=un-substituted or substituted aryl or alkyl group; R is hydroxy or hydrogen, X is chlorine, bromine and iodine. The present invention also relates to a process for the preparation thereof.

The present invention discloses Octenidine based compounds of formula (A) or formula (B) and formula (C) where in, n=1,2,3,4 and R=un-substituted or substituted aryl or alkyl group; R is hydroxy or hydrogen, X is chlorine, bromine and iodine. The present invention also relates to a process for the preparation thereof.